✓Tender information last checkedLast checked 6 Oct 2026, 18:11.
Opportunity overview
The Welsh Blood Service (WBS) requires an advanced automated haematology analysis system to support blood donor assessment, blood component quality monitoring, research and innovation activities. The proposed solution will be required to provide automated full blood count (FBC) analysis, 5-part white cell differential capability and integrated reticulocyte analysis on the primary analyser. Of particular interest are systems capable of generating the data required to support emerging donor health assessment methodologies, including FlowScore calculation and reticulated haemoglobin analysis for the early detection of iron deficiency in blood donors.
The requirement is includes advanced analytical capabilities that support the unique operational needs of a blood establishment. These include fluorescence platelet counting with high accuracy at low platelet concentrations, reticulated platelet measurement, low-level white cell enumeration suitable for blood component quality monitoring, and the ability to perform blood component testing without the need for separate instrumentation. Suppliers should be able to demonstrate how their platforms support routine blood component quality control programmes through dedicated blood bank functionality and provide evidence of successful implementation within blood services, blood centres or comparable blood establishments. WBS is particularly interested in solutions that are supported by robust External Quality Assessment (EQA/EQAS) programmes and can demonstrate meaningful peer group benchmarking through sufficient participant numbers using the same analyser platform and methodology. Suppliers should be able to demonstrate compliance with applicable medical device regulations, support quality and regulatory requirements through a mature quality management system and provide resilient service and maintenance arrangements that minimise downtime and ensure continuity of critical testing services.
Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.
2 published notice versions reviewed by ProcuraAxis.
2 VERSIONS
1
080964-2026Preliminary market engagement notice on Find a Tender ·
2
094438-2026Tender notice on Find a Tender ·
PROCURAAXIS ANALYSIS
ProcuraAxis Analysis
Our approved analysis of the opportunity appears below the official tender information.
ANALYSIS PREVIEW
Opportunity intelligence at a glance
Velindre University NHS Trust, through the Welsh Blood Service, is seeking an automated haematology testing system for donor assessment, blood-component quality monitoring, research and innovation. The system must provide FBC, five-part differential and integrated reticulocyte analysis, with specialist blood-bank testing capability and resilient maintenance support.
Who this may suit
Best suited to suppliers of automated haematology analyser platforms with blood-service implementation experience, advanced platelet/white-cell testing functionality, EQA/EQAS support, medical-device regulatory compliance and established service cover.
Key points identified
Core analyser capabilityAutomated FBC analysis, 5-part white-cell differential and integrated reticulocyte analysis on the primary analyser.Evidence: “provide automated full blood count (FBC) analysis, 5-part white cell differential capability and integrated reticulocyte analysis on the primary analyser”
Donor iron-deficiency analysisSystems capable of supporting FlowScore calculation and reticulated haemoglobin analysis are of particular interest.Evidence: “Of particular interest are systems capable of generating the data required to support… FlowScore calculation and reticulated haemoglobin analysis”
Specialist blood-component testingFluorescence platelet counting at low platelet concentrations, reticulated platelet measurement, low-level white-cell enumeration, and blood-component testing without separate instrumentation.Evidence: “These include fluorescence platelet counting with high accuracy at low platelet concentrations, reticulated platelet measurement, low-level white cell enumeration… and the ability to perform blood component testing without the need for separate instrumentation.”
96% approved-analysis confidence8 supplier criteria identified3 risks or unknowns
ProcuraAxis structures information found in published procurement records, checks the result for consistency and publishes only approved analysis. Confidence describes the completeness and consistency of the available source information; it is not a guarantee of eligibility or contract award.
Velindre University NHS Trust, through the Welsh Blood Service, is seeking an automated haematology testing system for donor assessment, blood-component quality monitoring, research and innovation. The system must provide FBC, five-part differential and integrated reticulocyte analysis, with specialist blood-bank testing capability and resilient maintenance support.
Who this may suit
Best suited to suppliers of automated haematology analyser platforms with blood-service implementation experience, advanced platelet/white-cell testing functionality, EQA/EQAS support, medical-device regulatory compliance and established service cover.
Key deliverables
Automated full blood count analysis
Five-part white-cell differential
Integrated reticulocyte analysis on the primary analyser
Automated FBC analysis, 5-part white-cell differential and integrated reticulocyte analysis on the primary analyser.
View supporting evidence
“provide automated full blood count (FBC) analysis, 5-part white cell differential capability and integrated reticulocyte analysis on the primary analyser”
Donor iron-deficiency analysis
94% confidence
Systems capable of supporting FlowScore calculation and reticulated haemoglobin analysis are of particular interest.
View supporting evidence
“Of particular interest are systems capable of generating the data required to support… FlowScore calculation and reticulated haemoglobin analysis”
Specialist blood-component testing
98% confidence
Fluorescence platelet counting at low platelet concentrations, reticulated platelet measurement, low-level white-cell enumeration, and blood-component testing without separate instrumentation.
View supporting evidence
“These include fluorescence platelet counting with high accuracy at low platelet concentrations, reticulated platelet measurement, low-level white cell enumeration… and the ability to perform blood component testing without the need for separate instrumentation.”
Blood-bank functionality
97% confidence
Demonstrate support for routine blood-component quality-control programmes through dedicated blood-bank functionality.
View supporting evidence
“Suppliers should be able to demonstrate how their platforms support routine blood component quality control programmes through dedicated blood bank functionality”
Relevant implementation experience
98% confidence
Evidence of successful implementation within blood services, blood centres or comparable blood establishments.
View supporting evidence
“provide evidence of successful implementation within blood services, blood centres or comparable blood establishments”
EQA/EQAS and peer benchmarking
97% confidence
Robust EQA/EQAS programme support and meaningful peer-group benchmarking with sufficient users of the same analyser platform and methodology.
View supporting evidence
“supported by robust External Quality Assessment (EQA/EQAS) programmes and can demonstrate meaningful peer group benchmarking through sufficient participant numbers using the same analyser platform and methodology”
Regulatory and quality management
97% confidence
Demonstrate compliance with applicable medical-device regulations and a mature quality management system.
View supporting evidence
“demonstrate compliance with applicable medical device regulations, support quality and regulatory requirements through a mature quality management system”
Supplier eligibility criteria
99% confidence
Unknown; no specific exclusion, financial-standing or selection criteria are supplied.
View supporting evidence
No eligibility criteria are stated in the supplied notice data.
COMMERCIAL AND DELIVERY
Contract intelligence
Commercial
Estimated contract value
99% confidence
Up to GBP 409,496.88.
View supporting evidence
Lot 1 value: 409496.88 GBP; process value_max: 409496.88 GBP.
Contract term
99% confidence
Unknown.
View supporting evidence
Contract start and end dates are not provided.
Pricing and payment terms
99% confidence
Unknown.
View supporting evidence
No pricing schedule or payment terms are supplied.
Delivery
Delivery area
97% confidence
UKL22, United Kingdom.
View supporting evidence
Delivery location region is listed as UKL22, United Kingdom.
Buyer location
99% confidence
Cardiff, CF15 7QZ, United Kingdom.
View supporting evidence
Buyer location is listed as Cardiff, CF15 7QZ.
Service continuity
98% confidence
Provide resilient service and maintenance arrangements that minimise downtime and maintain continuity of critical testing services.
View supporting evidence
“provide resilient service and maintenance arrangements that minimise downtime and ensure continuity of critical testing services”
PROCEDURE
How to respond
Procedure
99% confidence
Open procedure.
View supporting evidence
Procurement method details: Open procedure.
Opportunity status
99% confidence
Open tender.
View supporting evidence
Display status: open; source status: active.
Submission deadline
99% confidence
4 November 2026, 12:00 UTC.
View supporting evidence
Submission deadline: 2026-11-04T12:00:00+00:00.
Notice source
99% confidence
Find a Tender tender notice.
View supporting evidence
Notice type: Tender notice on Find a Tender.
RISKS AND UNKNOWNS
Points requiring attention
Specialist functional fit
96% confidence
The required blood-establishment and blood-component quality-control capabilities are specialised; suppliers should evidence each capability clearly.
View supporting evidence
The notice specifies advanced platelet, white-cell and blood-component testing functions alongside dedicated blood-bank functionality.
Peer-group benchmarking evidence
94% confidence
The buyer expects meaningful peer benchmarking based on sufficient participants using the same analyser platform and methodology; adequacy thresholds are not stated.
View supporting evidence
“meaningful peer group benchmarking through sufficient participant numbers using the same analyser platform and methodology”
Service resilience
96% confidence
Maintenance and support arrangements will be important because the system supports critical testing services; service-level requirements are not stated.
View supporting evidence
The notice requires arrangements that “minimise downtime and ensure continuity of critical testing services”.
ProcuraAxis analysis supplements, but does not replace, the original notice and tender documents. Always verify eligibility, deadlines and commercial terms with the issuing authority.
Continue in your ProcuraAxis workspaceFree account · Full approved analysis